Evidence map›Paper›PMID 31701330›Full record

ArticleJournal of neurology2020

Susac's syndrome as an immune-related adverse event after pembrolizumab: a case report.

M De Groot, A Compter, A J De Langen, D Brandsma

Abstract readCase ReportsLetter
PubMed Publisher
In one paragraph

Article in Journal of neurology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Immune checkpoint inhibitor-related hearing loss: a systematic review and analysis of individual patient data.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2023
    Pooled it
  3. Article
  4. Review
  5. Article
  6. Sudden onset hearing loss as initial presentation of Susac syndrome: a rare case report and brief review.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

M De GrootDepartment of Neuro-Oncology, Netherlands Cancer Institute-Antoni Van Leeuwenhoek, PO Box 90203, 1006 BE, Amsterdam, The Netherlands. ma.d.groot@nki.nl.
A CompterDepartment of Neuro-Oncology, Netherlands Cancer Institute-Antoni Van Leeuwenhoek, PO Box 90203, 1006 BE, Amsterdam, The Netherlands.
A J De LangenDepartment of Thoracic Oncology, Netherlands Cancer Institute-Antoni Van Leeuwenhoek, Amsterdam, The Netherlands.
D BrandsmaDepartment of Neuro-Oncology, Netherlands Cancer Institute-Antoni Van Leeuwenhoek, PO Box 90203, 1006 BE, Amsterdam, The Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Antibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalCarcinoma, Non-Small-Cell LungFemaleHumansLung NeoplasmsMiddle AgedSusac SyndromeAntibodies, Monoclonal, HumanizedAntineoplastic Agents, Immunologicalpembrolizumab

Identifiers

PMID31701330

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.